Andy
Retired committee member
Abstract
Introduction:
We aimed to explore the prevalence of carbohydrate (lactose and fructose) intolerance in patients with disorders of gut-brain interaction (DGBI), and to characterize those patients in terms of gastrointestinal and non-gastrointestinal symptoms.
Methods:
DGBI patients who were referred to the Physiology Unit of our Hospital between May 2022 and December 2023 for lactose (25g) and fructose (25g) breath tests were prospectively included. Patients were required to have a negative glucose breath test, prior to lactose and fructose breath tests, and to have completed the adult carbohydrate perception questionnaire (aCPQ) during each breath test. Intolerance was defined as an increase of ≥20 mm in the visual analog scale (VAS) score from baseline in at least one of the 5 symptoms (pain, nausea, bloating, flatulence, diarrhea) assessed with the aCPQ.
Results:
Among the 301 DGBI patients included in our analysis, 178 (59.1%) had carbohydrate intolerance. Carbohydrate-intolerant patients were significantly more likely to be female (p-value < 0.001), to have 2 or more DGBI (p-value= 0.001), to have lactose maldigestion (p-value< 0.001) and fructose malabsorption (p-value= 0.023), higher IBS and somatic symptom severity, and lower quality of life (p-value < 0.001) compared to patients without carbohydrate intolerance. The binary logistic regression showed that lactose maldigestion (p-value= 0.001), as well as somatic symptoms (p-value= 0.025), were independently associated with carbohydrate intolerance (Nagelkerke R Square= 0.206).
Discussion:
Carbohydrate intolerance affects a substantial group of DGBI patients, impacting their quality of life and symptom severity. Further research is needed to explore the underlying mechanisms in patients who do not have carbohydrate malabsorption/maldigestion.
Paywall
Introduction:
We aimed to explore the prevalence of carbohydrate (lactose and fructose) intolerance in patients with disorders of gut-brain interaction (DGBI), and to characterize those patients in terms of gastrointestinal and non-gastrointestinal symptoms.
Methods:
DGBI patients who were referred to the Physiology Unit of our Hospital between May 2022 and December 2023 for lactose (25g) and fructose (25g) breath tests were prospectively included. Patients were required to have a negative glucose breath test, prior to lactose and fructose breath tests, and to have completed the adult carbohydrate perception questionnaire (aCPQ) during each breath test. Intolerance was defined as an increase of ≥20 mm in the visual analog scale (VAS) score from baseline in at least one of the 5 symptoms (pain, nausea, bloating, flatulence, diarrhea) assessed with the aCPQ.
Results:
Among the 301 DGBI patients included in our analysis, 178 (59.1%) had carbohydrate intolerance. Carbohydrate-intolerant patients were significantly more likely to be female (p-value < 0.001), to have 2 or more DGBI (p-value= 0.001), to have lactose maldigestion (p-value< 0.001) and fructose malabsorption (p-value= 0.023), higher IBS and somatic symptom severity, and lower quality of life (p-value < 0.001) compared to patients without carbohydrate intolerance. The binary logistic regression showed that lactose maldigestion (p-value= 0.001), as well as somatic symptoms (p-value= 0.025), were independently associated with carbohydrate intolerance (Nagelkerke R Square= 0.206).
Discussion:
Carbohydrate intolerance affects a substantial group of DGBI patients, impacting their quality of life and symptom severity. Further research is needed to explore the underlying mechanisms in patients who do not have carbohydrate malabsorption/maldigestion.
Paywall
